research Sustained hair regrowth with ritlecitinib to Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.
Search
for
Sort by
Research
690-720 / 1000+ resultsresearch FRI-02 FROM GIRLS TO BOYS TO OLDER MEN, THE INTERESTING TALE OF THE GUEVEDOCES AND 5-ALPHA REDUCTASE INHIBITORS
The discovery of 5α-reductase deficiency in guevedoces led to the development of important urologic medications.
research First drug for severe alopecia recommended by NICE could benefit 14,000 patients
Ritlecitinib can help about 14,000 people with severe hair loss.
research Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata
Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
research No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study
Oral 5-alpha-reductase inhibitors for hair loss don't increase heart risk.
research Effect of 5-alpha reductase inhibitors in animal models of Parkinson’s disease
5-alpha reductase inhibitors may help protect the brain and gut in Parkinson's disease.
research Redefining Drug Discovery: A Review of Drug Repurposing –Approaches, Benefits and Breakthroughs
Drug repurposing finds new uses for existing drugs, speeding up treatment availability and reducing costs.
research How to manage an 18-20 year old with hair loss that is not improved with ketoconazole?
Ritlecitinib may help young adults with severe alopecia areata when ketoconazole fails.
![Synthesis and In Vitro Study of 17β-[N-Ureylene-N,N′-Disubstituted]-4-Methyl-4-Aza-5α-Androstan-3-Ones as Selective Inhibitors of Type I 5α-Reductase](/images/research/d19df8a7-8de6-4430-8a0d-4ffa1f502985/small/15608.jpg)
research Synthesis and in vitro study of 17β-[N-ureylene-N,N′-disubstituted]-4-methyl-4-aza-5α-androstan-3-ones as selective inhibitors of type I 5α-reductase
New compounds were made that effectively block a specific enzyme related to androgen conditions.
research The Identification of multi-target Inhibitors of Wolbachia pipientis and Onchocerca volvulus by molecular simulations
Adapalene, Diosmin, and Azelastine could be repurposed to treat onchocerciasis.
research Allogeneic Hair Transplantation with Enhanced Survival by Anti-ICAM-1 Antibody with Short-Term Rapamycin Treatment in Nonhuman Primates
Using an anti-ICAM-1 antibody with rapamycin improves hair transplant survival in monkeys.
research Topikal Retinoidler
Tretinoin is used topically to treat acne, skin aging, and various skin conditions.
research An industry update: what’s new in the field of therapeutic delivery this month?
New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.
research Pharmacokinetic parameters and mechanisms of inhibition of rat type 1 and 2 steroid 5α-reductases: determinants for different in vivo activities of GI198745 and finasteride in the rat 3 3Abbreviations: r5AR1, rat 5α-reductase 1; r5AR2, rat 5α-reductase 2; and DHT, dihydrotestosterone.
GI198745 is more potent and longer-lasting than finasteride, potentially better for treating hair loss.
research Upadacitinib for management of alopecia areata and rheumatoid arthritis: Letter to the editor
Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.
research Drug Repurposing Patent Applications July–September 2025
New drug uses show promise but need more research.
research Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.
research PD23-01 INHIBITOR OF 5A-REDUCTASE TYPES II PROMOTES THE INFILTRATION OF CD8+T CELLS IN BPH TISSUES.
Finasteride increases CD8+ T cells in BPH tissues.
research Novel inhibitors of 5α-reductase
New research is needed to create better drugs that block the enzyme responsible for conditions like male baldness and prostate enlargement.
research Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
research Lichenoid dermatitis from interferon alpha-2a in a patient with metastatic renal cell carcinoma and seronegative HCV
A patient with advanced kidney cancer and no hepatitis C developed skin inflammation due to a drug called interferon alpha-2a.
research Peripheral Neuroprotective and Immunomodulatory Effects of 5α-Reductase Inhibitors in Parkinson’s Disease Models
Dutasteride may help protect neurons and reduce inflammation in Parkinson's disease.
research New insights into the phenomenon of remissions and relapses in autoimmune diseases and the puzzle of benign autoantibodies in healthy individuals
Autoimmune diseases with high tissue recovery often relapse and remit, while those with low recovery rarely remit.
research 5α-Reductase inhibitor therapy: Should physicians be concerned with persistent diminished libido, erectile dysfunction and depression in a subset of patients?
Some patients may experience lasting sexual dysfunction, depression, and other side effects from 5α-reductase inhibitor therapy.
research The Impact of the 5α-Reductase Inhibitors (5α-RIs) on Male Sexual Function and Psychological Well-Being
5α-reductase inhibitors can cause serious and possibly lasting sexual and psychological side effects.
research MP09-16 5-ALPHA REDUCTASE INHIBITORS FOR MALE LOWER URINARY TRACT SYMPTOMS: A COCHRANE SYSTEMATIC REVIEW AND META-ANALYSIS
5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.
research 67 Patterns of clinical response in patients with alopecia areata (AA) treated with ritlecitinib in the ALLEGRO phase 2b/3 and ongoing, phase 3, ALLEGRO-LT studies
Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.
research Androgenetic alopecia; drug safety and therapeutic strategies
Personalized treatment with inhibitors, minoxidil, and laser therapy helps hair loss.
research 5ARI and PSA: open questions
5ARI treatment improves PSA test accuracy for prostate cancer diagnosis.
research Trichoscopic Markers and Clinical Response Patterns With Ritlecitinib in Severe Alopecia Areata: 24‐Week Outcomes From a Prospective Real‐World Cohort
Ritlecitinib is effective and safe for treating severe alopecia areata, showing significant hair regrowth and improved mental health.